UNH · Q4 2025 Earnings

Cautious

UnitedHealth Group

Reported January 27, 2026

30-second summary

Q4 FY2025 revenue grew 12.2% YoY to $113.2B and adjusted EPS was $2.11, closing FY2025 at $447.6B revenue (+12%) and $16.35 adjusted EPS — above the ≥$16.25 floor management set in Q3 FY2025. The bigger news is forward: after two quarters of withdrawn cost frameworks, management re-issued a fully quantified FY2026 outlook — revenue >$439B (-2% YoY), adjusted EPS >$17.75, operating earnings >$24B at ~5.5% margin, and MCR of 88.8% ±50bps (management framed as -30bps vs reported FY2025 MCR of 89.1%, or -10bps vs adjusted 88.9%). The setup is now explicit: shrink the top line by 2%, expand operating margin by ~130bps, and let Optum Rx and Medicare growth offset commercial and Optum Health contraction. Note the FY2026 operating cash flow guide of >$18B is below FY2025's $19.7B — the press release attributes this to timing, with payments received in 2025 that were expected in 2026 pulling FY2025 OCF above plan.

Headline numbers

EPS

Q4 FY2025

$2.11

Revenue

Q4 FY2025

$113.20B

+12.2% YoY

Operating margin

Q4 FY2025

0.3%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$113.20B	+12.2%	$113.20B	+0.0%
EPS	$2.11	—	$2.92	-27.7%
Operating margin	0.3%	—	3.8%	-350bps

Guidance

UnitedHealth Group guides FY2026 revenue decline of 2% YoY to $439B+ with EPS growth of 4-9% and significant margin expansion (MCR improving 30 bps), signaling strategic shift to profitability and right-sizing over growth.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Revenue	FY2026	Greater than $439.0 billion	-2% YoY
Earnings Per Share (GAAP)	FY2026	Greater than $17.10	—
Adjusted Earnings Per Share	FY2026	Greater than $17.75	—
Operating Earnings	FY2026	Greater than $24.0 billion	—
Operating Margin	FY2026	~5.5%	—
Net Margin	FY2026	~3.6%	—
Medical Care Ratio	FY2026	88.8% ± 50 basis points	—
Operating Cost Ratio	FY2026	12.8% ± 50 basis points	—
Cash Flows from Operations	FY2026	Greater than $18.0 billion	—

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
UnitedHealthcare	$87.1B	+17.5%
Optum Health	$25.5B	-0.5%
Optum Insight	$5B	+5.5%
Optum Rx	$41.5B	+15.9%
UnitedHealthcare Employer & Individual	$19.7B	-0.3%
UnitedHealthcare Medicare & Retirement	$43.6B	+27.5%
UnitedHealthcare Community & State	$23.8B	+18.1%

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
UnitedHealthcare People Served	49.8 million
Optum Consumers Served	95 million (Health), 2.6 million (Fully Accountable Patients)
Medical Care Ratio (Adjusted)	91.5%
Operating Cost Ratio (Adjusted)	13.6%
Optum Rx Adjusted Scripts (Quarterly)	424 million
Optum Insight Contract Backlog	$31.1 billion
Operating Cash Flow (Full Year)	$19.7 billion
Debt-to-Capital Ratio	43.9%

Management tone

Q1 FY2025 operational excellence → Q2 FY2025 "we've made mistakes" reset → Q3 FY2025 "durable and accelerating growth in 2026 and beyond" → Q4 FY2025 "right-sizing and precise execution"

Three quarters ago management was selling integrated execution; two quarters ago the new CEO conceded pricing and operational mistakes; last quarter the language pivoted forward to "durable and accelerating growth in 2026"; this quarter the framing has hardened into "right-sizing across the enterprise" with explicit 2026 revenue decline. The press release language — "durable performance improvement and margin expansion through greater operating discipline and precise execution" — is a different posture from Q3 FY2025's "return to sustained growth." The 2% revenue contraction is the operational embodiment of the shift: management is no longer trying to defend the growth narrative and is instead trading top line for margin recovery.

The second shift is in how 2027 is being framed. In Q3 FY2025 Tim Noel quantified the 2026 commercial margin gap precisely (-150bps below the 7% low end) with a 2027 return to the 7–9% range. This quarter the 2027 conversation is dominated by the CMS advance notice and a $130B three-year Medicare funding reduction — Tim Noel deferred specific 2027 MA membership guidance pending CMS finalization, and Kevin Fishbeck pressed on whether UnitedHealth expects disproportionate coding impact (1.8% risk model normalization + 1.5% chart review = 3.3% headwind) vs peers. Management's answer that they expect impact "consistent with industry averages, not disproportionate" is the most important non-quantified disclosure of the call — it caps how much downside the coding intensity reset can be assumed to create, but only if that read holds.

The third shift is the move from candor to operational specificity in Optum Health. Justin Lake pressed on Q4 FY2025 Optum Health performance — Q4 reported a $2.78B operating loss and adjusted earnings of -$219M, with Krista setting $1.5B as the new go-forward baseline (excluding restructuring and the Optum Financial Services reclassification). The operational improvements disclosed — 20% network narrowing, 15% risk membership streamlining, EMR consolidation from 18 systems to 3, 30% of mature VBC patients already in target margin range — is the specificity Q2 FY2025's introspection lacked. The Texas reference market (750K+ patients, 4.5-star plan, 30% better total cost of care, 90 NPS) is being held up as the operating model the rest of the book is being rebuilt toward.

Q&A highlights

Josh Raskin · Nefron Research

Asked about MA membership decline trajectory (mid-teens decline expected), whether the company believes MA cycle has bottomed, and the importance of core MA book to other segments like OptumHealth.

Tim Knoll stated 2026 strategy focused on margin recovery rather than membership targets, with pricing assumptions holding firm and 50 basis points margin improvement expected. For 2027, management acknowledged advance notice rate reductions are disappointing given $130B in cuts over three years, but deferred specific 2027 membership guidance pending CMS finalization. Emphasized integrated business model and value-based care focus will be critical in lower-rate environment.

2026 MA membership loss: 1.3-1.4 millionMedicare margin improvement: ~50 basis points in 2026Medicare medical cost trend 2025: 7.5%, 2026 expectation: 10%Medicare funding reductions over 3 years: $130 billion

Justin Lake · Wolfe Research

Asked about OptumHealth Q4 performance volatility (Q4 OI ~$3B vs Q3 ~$2.3B), which was unexpected given timing in year, and what gives confidence in more stable 2026 performance.

Management attributed Q4 underperformance to restructuring actions, one-time items, and elevated but expected medical trends. Excluding restructuring, adjusted earnings baseline ~$1.5B. Expressed confidence based on reorientation back to original integrated value-based care purpose, network optimization (narrowed network 20%), risk streamlining (15%), and operational discipline improvements (consolidated EMRs from 18 to 3).

OptumHealth Q4 adjusted OI baseline: ~$1.5 billionNetwork narrowing: ~20% reduction since prior yearRisk membership streamlining: ~15% reductionEMR consolidation: from 18 to 3 systems; ~100% of employed provider groups on one of three strategic EMRs

Kevin Fishbeck · Bank of America

Focused on 2027 MA rate update coding components (risk model normalization 1.8%, chart review 1.5% = 3.3% headwind). Asked if UnitedHealth expects disproportionate impact vs. industry given superior coding capabilities, and if still confident in achieving 5% margin target for OptumHealth value-based care.

Management stated no expectation of disproportionate coding impact vs. industry peers. On OptumHealth 5% margin target, Krista Opsahl expressed confidence based on execution improvements and high-performing market examples where margins already meet or exceed long-term targets. Emphasized execution and consistency as primary drivers, with 30% of mature value-based care patients already in target margin range.

Expected coding impact: consistent with industry averages, not disproportionateOptumHealth long-term margin target: 6-8% (5% mentioned as part of discussion but actual target is 6-8%)Mature value-based care patients performing in target range: ~30%Total cost of care improvement in high-performing markets: ~30% vs competitors

Scott Fidel · Goldman Sachs

Asked for breakdown of 1.3-1.4M commercial risk life decline between group vs. exchange, and margin progression expectations for both segments in 2026, noting exchange profit rebate plan.

Dan Scorsone provided specific breakdown: $500K+ from exchange business, remainder from general market decline, pricing posture, and migration to self-funded offerings. For margins: exchange business expected to return to positive margins in 2026 (1% +/- 1%), compared to no significant earnings contribution historically. Group business expected to close more than half the gap to historical margin range in 2026, with full recovery in 2027.

Commercial risk membership decline attribution: $500K+ from exchange, remainder from market decline and migrationExchange business expected margin: ~1% ± 1% in 2026Exchange business historical contribution: not significant earnings contributorGroup business margin progression: expecting >50% of gap closure to historical range in 2026, full closure in 2027

Lisa Gill · JPMorgan

Asked about Part D seasonality changes due to IRA implementation and 2026 impact on earnings progression, plus specifics on 800 new OptumRx clients in terms of trends and why they're selecting OptumRx.

Management explained IRA implementation created more even seasonal trending throughout 2026 vs. historical patterns. Emphasized 2026 benefit design aligned with industry-wide approach. For OptumRx new clients, highlighted three winning factors: affordability (OptumRx generates $100B+ in savings annually for clients, $1B+ for members), transparency (transparent P&T committee, supply chain visibility, 100% rebate pass-through commitment by 2028), and execution (high NPS across channels, removal of reauthorization for 180+ drugs reducing prior authorizations by 10%).

OptumRx new clients in 2026: 800 relationshipsOptumRx client-level savings: $100+ billion annuallyMember/patient-level savings: $1+ billion annuallyPrior authorization reduction: >10% from elimination of reauth for 180+ drugs

Answers to last quarter's watch list

Whether FY2025 MCR and OCR guidance is re-issued at the Q4 FY2025 print or quietly remains absent. Reissued — but for FY2026, not for FY2025 (which closed at adjusted MCR 88.9% and adjusted OCR 12.9%). The new FY2026 bands are 88.8% ±50bps and 12.8% ±50bps, doubled from the ±25bps frame that was withdrawn in Q3 FY2025. Framework restored, but with more room to maneuver.

Resolved positively

Q4 FY2025 MCR specifically — does it stay near Q3 FY2025 levels or step further toward 90%? Stepped meaningfully higher to 91.5% adjusted in Q4 FY2025, pushing FY2025 adjusted MCR to 88.9%. The $16.25 EPS floor was defended (FY2025 adjusted EPS $16.35, +$0.10) but Q4 FY2025 GAAP EPS collapsed to $0.01 and operating margin to 0.3%, reflecting restructuring charges and the elevated medical trend.

Resolved negatively

Initial FY2026 guidance shape. Fully quantified framework issued: revenue >$439B, adjusted EPS >$17.75, GAAP EPS >$17.10, operating earnings >$24B, operating margin ~5.5%, net margin ~3.6%, MCR 88.8% ±50bps, OCR 12.8% ±50bps, OCF >$18B. This is the most complete framework UnitedHealth has issued since Q1 FY2025 and resolves the question of whether the guidance vacuum would extend into 2026.

Resolved positively

OptumHealth — flat YoY → positive YoY transition. Re-decelerated to -0.5% in Q4 FY2025 from 0% in Q3 FY2025. The trajectory did not inflect positive, and management's 2026 framing now leans on operational restructuring (20% network narrowing, 15% risk streamlining, EMR consolidation) rather than revenue stabilization to drive the VBC margin recovery.

Resolved negatively

First independent expert review report. Hemsley noted in closing remarks that the first independent reports on business practices and risk assessment in pharmacy services and care management were published in December, with remediation recommendations to be completed and reported no later than March 2026. Further reviews are in process.

Resolved positively

What to watch into next quarter

Q1 FY2026 MCR vs the 88.8% ±50bps band. Q4 FY2025 came in at 91.5% adjusted — for the FY2026 guide to hold, Q1 FY2026 needs to land notably below the midpoint given management's stated seasonal pattern (first-half MCR notably below midpoint, second-half notably above). A Q1 FY2026 print above 89.3% (top of band) would force a guidance reset within one quarter of the framework being re-issued.

Operating cash flow trajectory vs the >$18B FY2026 guide. The press release attributes the FY2025 $19.7B (1.5x net income) outperformance partly to timing — payments received in 2025 that were expected in 2026 — with 2026 guided to ~1.1x net income conversion. Q1 FY2026 OCF and the working capital build/release commentary will reveal whether the conservative cash flow guide is purely timing reversal or whether structural drag is embedded.

MA membership at AEP close. Management has guided to 1.3–1.4M decline. Actual AEP results — and whether competitor disruption (broker commissions, plan exits) drove disproportionate UNH retention or further losses — will frame whether the 2026 ~50bps Medicare margin improvement is achievable on the smaller base.

2027 CMS final rate notice and management's response. The advance notice 3.3% coding headwind plus the $130B three-year funding context will be finalized in the coming months. Whether management quantifies a 2027 EPS bridge at that point, or defers again, determines whether the 2026 guide is a floor or a peak.

Optum Health Q1 FY2026 revenue trajectory and recast baseline. Q4 FY2025 -0.5% suggests the operational restructuring (network narrowing, risk streamlining) is now showing up as a revenue headwind. The FY2026 Optum Health guide of >$2.2B in operating earnings against the recast $1.45B FY2025 base (post Optum Financial Services reclassification) is a +52% YoY recovery — Q1 FY2026 needs to demonstrate the leaner book is more profitable per patient or that target loses credibility.

Sources

UnitedHealth Group Q4 FY2025 Press Release / Form 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/731766/000073176626000025/a991unherq42025.htm
UnitedHealth Group Q4 FY2025 earnings call Q&A — Stephen Hemsley, Tim Noel, Patrick Conway, Wayne DeVeydt, Krista, Bobby; Josh Raskin (Nephron Research), Justin Lake (Wolfe Research), Kevin Fishbeck (Bank of America), Lisa Gill (JPMorgan)
Tapebrief UNH Q3 FY2025 and Q2 FY2025 briefs (prior coverage)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.